Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Status:
Withdrawn
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This study employs a 1:1 randomization of patients to receive romidepsin alone verses
romidepsin plus pralatrexate for the treatment of patients with relapsed or refractory
peripheral T-cell lymphoma (PTCL). The primary objectives will be to identify a 75%
improvement in progression free survival (PFS) among patients receiving the combination
compared to single agent romidepsin.